Motive and Telefónica have successfully completed a proof of concept (PoC) showcasing seamless authentication using GSMA Open Gateway's Number Verification API. Debuted at the Google Cloud booth ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a developer of targeted radiotherapies, announced the introduction of ATNM-400, a new radiotherapy for prostate cancer, and detailed ...

ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting - Actinium is ...

Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure (PRNewsfoto/Actinium ...

Risk Warning: Your Capital is at Risk. This iron ore trading guide focuses on the different ways you can trade iron ore as a commodity. We provide a list of regulated brokers in for traders who are ...

Sandesh Seth, Chairman and CEO at Actium Pharmaceuticals, Inc. commented: "We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating ...

NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Actinium Pharmaceuticals (ATNM) has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to expand Actimab-A’s mutation agnostic mechanism of action. The ...